1. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial. Issue 10 (8th June 2017) Authors: Wysham, Carol; Bonadonna, Riccardo C.; Aroda, Vanita R.; Puig Domingo, Manuel; Kapitza, Christoph; Stager, William; Yu, Christine; Niemoeller, Elisabeth; Souhami, Elisabeth; Bergenstal, Richard M. Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 10(2017) Page Start: 1408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring. Issue 4 (28th February 2017) Authors: Bergenstal, Richard M.; Strock, Ellie; Mazze, Roger; Powers, Margaret A.; Monk, Arlene M.; Richter, Sara; Souhami, Elisabeth; Ahrén, Bo Journal: Diabetes/metabolism research and reviews Issue: Volume 33:Issue 4(2017) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial. Issue 8 (12th May 2022) Authors: Yang, Wenying; Dong, Xiaolin; Li, Qingju; Cheng, Zhifeng; Yuan, Guoyue; Liu, Ming; Xiao, Jianzhong; Gu, Shenghong; Niemoeller, Elisabeth; Chen, Lijuan; Ping, Lin; Souhami, Elisabeth Journal: Diabetes, obesity & metabolism Issue: Volume 24:Issue 8(2022) Page Start: 1522 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial. Issue 1 (6th October 2021) Authors: Davies, Melanie J.; Rosenstock, Julio; Ali, Amar; Russell‐Jones, David; Souhami, Elisabeth; Palmer, Karen; Ji, Chen; Niemoeller, Elisabeth; Skolnik, Neil Journal: Diabetes, obesity & metabolism Issue: Volume 24:Issue 1(2022) Page Start: 34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial. Issue 12 (23rd August 2022) Authors: McCrimmon, Rory J.; Home, Philip; Cheng, Alice; Giorgino, Francesco; Fonseca, Vivian; Souhami, Elisabeth; Alvarez, Agustina; Picard, Pascaline; Rosenstock, Julio Journal: Diabetes, obesity & metabolism Issue: Volume 24:Issue 12(2022) Page Start: 2391 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents. Issue 12 (7th July 2017) Authors: Davies, Melanie J.; Leiter, Lawrence A.; Guerci, Bruno; Grunberger, George; Ampudia‐Blasco, F. Javier; Yu, Christine; Stager, William; Niemoeller, Elisabeth; Souhami, Elisabeth; Rosenstock, Julio Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 12(2017) Page Start: 1798 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial. Issue 9 (28th May 2020) Authors: Del Prato, Stefano; Frias, Juan Pablo; Blonde, Lawrence; Aroda, Vanita R.; Shehadeh, Niam; Saremi, Aramesh; Dex, Terry; Niemoeller, Elisabeth; Souhami, Elisabeth; Liu, Minzhi; Rosenstock, Julio Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 9(2020) Page Start: 1567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes. (3rd June 2019) Authors: Schmider, Wolfgang; Belder, Rene; Lee, Michelle; Niemoeller, Elisabeth; Souhami, Elisabeth; Frias, Juan P. Journal: Current medical research and opinion Issue: Volume 35:Number 6(2019) Page Start: 1081 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial. Issue 11 (25th July 2022) Authors: Yuan, Xiaoyong; Guo, Xiaohui; Zhang, Junqing; Dong, Xiaolin; Lu, Yibing; Pang, Wuyan; Gu, Shenghong; Niemoeller, Elisabeth; Ping, Lin; Nian, Gaowei; Souhami, Elisabeth Journal: Diabetes, obesity & metabolism Issue: Volume 24:Issue 11(2022) Page Start: 2182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening. Issue 6 (4th May 2021) Authors: Rosenstock, Julio; Blonde, Lawrence; Aroda, Vanita R.; Frias, Juan; Souhami, Elisabeth; Ji, Chen; Niemoeller, Elisabeth; Del Prato, Stefano Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 6(2021) Page Start: 1331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗